{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:05:11Z","timestamp":1763762711823,"version":"3.45.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cld.2025.09.001","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:25:47Z","timestamp":1761654347000},"page":"17-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing Alcohol Use Disorder in Alcohol-Related Liver Disease"],"prefix":"10.1016","volume":"30","author":[{"given":"Mashal","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahil","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cld.2025.09.001_bib1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.35946\/arcr.v35.2.07","article-title":"Global alcohol-attributable deaths from cancer, liver cirrhosis, and injury in 2010","volume":"35","author":"Rehm","year":"2013","journal-title":"Alcohol Res Curr Rev"},{"issue":"3","key":"10.1016\/j.cld.2025.09.001_bib2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/hep.32531","article-title":"Alcohol use disorder in community management of chronic liver diseases","volume":"77","author":"Leggio","year":"2023","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2025.09.001_bib3","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/acer.13884","article-title":"Reduction in nonabstinent WHO drinking risk levels and change in risk for liver disease and positive AUDIT-C scores: prospective 3-year follow-up results in the US general population","volume":"42","author":"Knox","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"10.1016\/j.cld.2025.09.001_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and treatment of alcohol-associated liver disease: a review","volume":"326","author":"Singal","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cld.2025.09.001_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.livres.2018.11.002","article-title":"Alcoholic liver disease: A current molecular and clinical perspective","volume":"2","author":"Ohashi","year":"2018","journal-title":"Liver research"},{"issue":"5","key":"10.1016\/j.cld.2025.09.001_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cld.806","article-title":"Epidemiology of alcohol use and alcoholic liver disease","volume":"13","author":"Mellinger","year":"2019","journal-title":"Clinical liver disease"},{"issue":"5","key":"10.1016\/j.cld.2025.09.001_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101127","article-title":"Racial, ethnic, and socioeconomic disparities impact post-liver transplant survival in patients with hepatocellular carcinoma","volume":"28","author":"Huang","year":"2023","journal-title":"Ann Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2025.09.001_bib8","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.cgh.2020.09.033","article-title":"In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent","volume":"19","author":"Bittermann","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.cld.2025.09.001_bib9","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","article-title":"The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking","volume":"158","author":"Bush","year":"1998","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2025.09.001_bib10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1553-2712.2008.00085.x","article-title":"Caffeinated cocktails: energy drink consumption, high-risk drinking, and alcohol-related consequences among college students","volume":"15","author":"O\u2019Brien","year":"2008","journal-title":"Acad Emerg Med"},{"issue":"11","key":"10.1016\/j.cld.2025.09.001_bib11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br J Addiction"},{"issue":"2","key":"10.1016\/j.cld.2025.09.001_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.09.001_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.cld.2025.09.001_bib14","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","article-title":"Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.cld.2025.09.001_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/HEP.0000000000000825","article-title":"Recurrent alcohol-associated hepatitis is common and is associated with increased mortality","volume":"80","author":"Gratac\u00f3s-Gin\u00e8s","year":"2024","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.cld.2025.09.001_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159775","article-title":"The circulating proteomic signature of alcohol-associated liver disease","volume":"7","author":"Luther","year":"2022","journal-title":"JCI insight"},{"key":"10.1016\/j.cld.2025.09.001_bib17","doi-asserted-by":"crossref","first-page":"s3","DOI":"10.1111\/j.1521-0391.2003.tb00492.x","article-title":"Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence","volume":"12","author":"Littleton","year":"2003","journal-title":"Am J Addict"},{"issue":"3","key":"10.1016\/j.cld.2025.09.001_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/ADM.0b013e318156c26f","article-title":"Acamprosate in alcohol dependence: implications of a unique mechanism of action","volume":"1","author":"Littleton","year":"2007","journal-title":"J Addiction Med"},{"issue":"17","key":"10.1016\/j.cld.2025.09.001_bib19","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.cld.2025.09.001_bib20","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2025.09.001_bib21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-015-0423-9","article-title":"Acamprosate: a review of its use in alcohol dependence","volume":"75","author":"Plosker","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.cld.2025.09.001_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/alcalc\/agh163","article-title":"Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system","volume":"40","author":"Lee","year":"2005","journal-title":"Alcohol Alcohol"},{"issue":"13","key":"10.1016\/j.cld.2025.09.001_bib23","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.cld.2025.09.001_bib24","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.cld.2025.09.001_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101095","article-title":"Safety of naltrexone in patients with cirrhosis","volume":"6","author":"Thompson","year":"2024","journal-title":"JHEP Reports"},{"issue":"1","key":"10.1016\/j.cld.2025.09.001_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.15288\/jsa.1977.38.96","article-title":"The disulfiram--ethanol reaction: a review","volume":"38","author":"Kitson","year":"1977","journal-title":"J Stud Alcohol"},{"key":"10.1016\/j.cld.2025.09.001_bib27","first-page":"1097","article-title":"Supervised disulfiram should be considered first-line treatment for alcohol use disorder","volume":"10","author":"Holt","year":"2024","journal-title":"J Addiction Med"},{"issue":"1","key":"10.1016\/j.cld.2025.09.001_bib28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/01.jcp.0000426185.68487.9a","article-title":"Psychotic symptoms after combined metronidazole-disulfiram use","volume":"33","author":"Luykx","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.cld.2025.09.001_bib29","series-title":"\u03b12\u03b4 and the mechanism of action of gabapentin in the treatment of pain","first-page":"565","author":"Maneuf","year":"2006"},{"issue":"9","key":"10.1016\/j.cld.2025.09.001_bib30","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/add.14655","article-title":"A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder","volume":"114","author":"Kranzler","year":"2019","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.cld.2025.09.001_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2025.09.001_bib32","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.cld.2025.09.001_bib33","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/acer.14408","article-title":"Safety of gabapentin prescribed for any indication in a large clinical cohort of 571,718 US veterans with and without alcohol use disorder","volume":"44","author":"Rentsch","year":"2020","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"10.1016\/j.cld.2025.09.001_bib34","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/s41386-021-00968-w","article-title":"Effects of topiramate on neural responses to alcohol cues in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial","volume":"46","author":"Wetherill","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.cld.2025.09.001_bib35","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.cld.2025.09.001_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1157.2000.tb02164.x","article-title":"Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons","volume":"41","author":"Gibbs","year":"2000","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.cld.2025.09.001_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1176\/appi.ajp.20230666","article-title":"Topiramate versus naltrexone for alcohol use disorder: a genotype-stratified double-blind randomized controlled trial","volume":"181","author":"Morley","year":"2024","journal-title":"Am J Psychiatr"},{"issue":"13","key":"10.1016\/j.cld.2025.09.001_bib38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1056\/NEJMra1715733","article-title":"Alcohol use in patients with chronic liver disease","volume":"379","author":"Fuster","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2025.09.001_bib39","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.eplepsyres.2014.03.011","article-title":"Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment","volume":"108","author":"Manitpisitkul","year":"2014","journal-title":"Epilepsy Res"},{"issue":"2\u20133","key":"10.1016\/j.cld.2025.09.001_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejphar.2004.03.065","article-title":"Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats","volume":"492","author":"Colombo","year":"2004","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.cld.2025.09.001_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2018.03.017","article-title":"Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis","volume":"28","author":"Pierce","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.cld.2025.09.001_bib42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG clinical guideline: alcohol-associated liver disease","volume":"119","author":"Jophlin","year":"2024","journal-title":"J Am Coll Gastroenterol"},{"key":"10.1016\/j.cld.2025.09.001_bib43","series-title":"Baclofen for the treatment of alcohol use disorder. GABAB receptor","first-page":"117","author":"Agabio","year":"2024"},{"issue":"7","key":"10.1016\/j.cld.2025.09.001_bib44","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/add.13787","article-title":"The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial","volume":"112","author":"Hauser","year":"2017","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.cld.2025.09.001_bib45","article-title":"Motivational interviewing for substance abuse","volume":"2011","author":"Smedslund","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.cld.2025.09.001_bib46","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/j.1360-0443.1997.tb02889.x","article-title":"Project MATCH secondary a priori hypotheses","volume":"92","year":"1997","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.cld.2025.09.001_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8279","article-title":"Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis","volume":"3","author":"Ray","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.cld.2025.09.001_bib48","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1176\/appi.ajp.2016.16050627","article-title":"A randomized controlled trial of ethyl glucuronide-based contingency management for outpatients with co-occurring alcohol use disorders and serious mental illness","volume":"174","author":"McDonell","year":"2017","journal-title":"Am J Psychiatr"},{"issue":"3","key":"10.1016\/j.cld.2025.09.001_bib49","article-title":"Alcoholics Anonymous and other 12-step programs for alcohol use disorder","volume":"3","author":"Kelly","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cld.2025.09.001_bib50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsat.2016.10.004","article-title":"Comparison of 12-step groups to mutual help alternatives for AUD in a large, national study: Differences in membership characteristics and group participation, cohesion, and satisfaction","volume":"73","author":"Zemore","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"10.1016\/j.cld.2025.09.001_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/adb0000237","article-title":"Systematic review of SMART Recovery: Outcomes, process variables, and implications for research","volume":"31","author":"Beck","year":"2017","journal-title":"Psychol Addict Behav"},{"issue":"3","key":"10.1016\/j.cld.2025.09.001_bib52","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2022.07.024","article-title":"A systematic review on the use of artificial intelligence in gynecologic imaging - background, state of the art, and future directions","volume":"166","author":"Shrestha","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.cld.2025.09.001_bib53","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/acer.14802","article-title":"Predicting heavy drinking during outpatient alcohol use treatment using machine learning","volume":"46","author":"Roberts","year":"2022","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.cld.2025.09.001_bib54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.20885\/enthusiastic.vol2.iss2.art3","article-title":"AI-based personalized virtual therapist for alcohol relapse","author":"Win","year":"2022","journal-title":"Enthusiastic"},{"key":"10.1016\/j.cld.2025.09.001_bib55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.alcohol.2021.01.007","article-title":"Wrist-worn alcohol biosensors: Applications and usability in behavioral research","volume":"92","author":"Wang","year":"2021","journal-title":"Alcohol"},{"issue":"4","key":"10.1016\/j.cld.2025.09.001_bib56","doi-asserted-by":"crossref","DOI":"10.2196\/35178","article-title":"Accuracy of wearable transdermal alcohol sensors: systematic review","volume":"24","author":"Brobbin","year":"2022","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.cld.2025.09.001_bib57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jbi.2016.09.001","article-title":"Health at hand: A systematic review of smart watch uses for health and wellness","volume":"63","author":"Reeder","year":"2016","journal-title":"J Biomed Inf"},{"issue":"1","key":"10.1016\/j.cld.2025.09.001_bib58","doi-asserted-by":"crossref","DOI":"10.2196\/30186","article-title":"Preliminary effectiveness of a remotely monitored blood alcohol concentration device as treatment modality: protocol for a randomized controlled trial","volume":"11","author":"Buono","year":"2022","journal-title":"JMIR research protocols"},{"issue":"2","key":"10.1016\/j.cld.2025.09.001_bib59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/psychiatry.IndianJPsychiatry_262_15","article-title":"Motivation to change and factors influencing motivation in alcohol dependence syndrome in a tertiary care hospital","volume":"59","author":"D'Souza","year":"2017","journal-title":"Indian J Psychiatry"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:01:34Z","timestamp":1763762494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125000820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1089326125000820"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.09.001","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Alcohol Use Disorder in Alcohol-Related Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}